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a b s t r a c t
High throughput GC–MS methods for quantiﬁcation of alkylresorcinols (AR), biomarkers of whole grain
wheat and rye intake, in plasma and adipose tissue and their metabolites in urine were developed and
optimised. Alkylresorcinols in plasma (200L) and adipose tissues (10–50mg) were extracted with
diethyl ether, whereas main AR metabolites such as DHBA and DHPPA and newly identiﬁed metabo-
lites in urine (50L) were extracted with ethyl acetate after enzymatic deconjugation. All extracts were
puriﬁed onOASIS-MAX solid phase extraction cartridges. Plasma and adipose tissue sample extractswere
then derivatised with triﬂuoroacetic anhydride and reconstituted in undecane, whereas AR metabolites
in urine samples were derivatised with BSTFA+TMCS (99:1, v/v, 100L). Prepared samples were quan-
tiﬁed by GC–MS (EI-SIM). Analysis of all compounds in the different matrices showed good selectivity,
sensitivity, linearity, precision (<15% within and between batches), adequate recovery (75–108%), and
short total run time (10–12min). The methods developed are applicable to large-scale sample sets such
as epidemiological studies.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Epidemiological studies have consistently shown inverse rela-
tionships between consumption of whole grain cereals and the risk
of developing several chronic diseases such as cardiovascular dis-
ease, type 2 diabetes and colorectal cancer [1–3]. Most studies rely
on self-reported intakes from food frequency questionnaires (FFQ),
Abbreviations: AR, alkylresorcinol; AT, adipose tissue; BSTFA, N,O-bis
(trimethylsilyl) triﬂuoroacetamide; CV, coefﬁcient of variation; DHBA glycine,
2-(3,5-dihydroxybenzamido) acetic acid; DHBA, 1,3-dihydroxy-benzoic acid;
DHCA, 3,5-dihydroxycinnamic acid; DHCA-amide, 3,5-dihydroxycinnamic acid
amide; DHPPA, 3-(3,5-dihydroxyphenyl)-propanoic acid; DHPPTA, 5-(3,5-
dihydroxyphenyl)pentanoic acid); EI, Electron impact ionization; FFQ, food
frequency questionnaires; GC–MS, gas chromatography–mass spectrometry; GLM,
general linear model; IS, internal standard; LOD, limit of detection; LOQ, limit of
quantiﬁcation;NCI, negative chemical ionization; SIM, selected ionmonitoring; SPE,
solid phase extraction; MS, mass spectrometry; TFAA, triﬂuoroacetic anhydride;
TMCS, trimethylchlorosilane.
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which are known to suffer from relatively large systematic and
random measurement errors [4]. Accurate whole grain intake data
acquisition via FFQ may be hampered by having few questions on
cereal foods, difﬁculties among consumers in recognizing whole
grain products, large variations in whole grain content in cereal
foods and lack of food composition data [5]. Therefore, dietary
biomarkers may provide an independent tool to overcome some
of these obstacles and a better way for objective ranking of whole
grain intake in epidemiological studies [6,7].
Alkylresorcinols (AR), a group of amphiphilic 1,3-dihydroxy-
5-alkyl phenolic lipids, have been suggested and evaluated as
biomarkers of whole grain wheat and rye intake in different popu-
lations [8–10] due to their almost exclusive presence in the outer
part of wheat and rye grains among commonly consumed foods
[11,12]. Homologues with odd alkyl chains of 17–25 carbons atoms
are themost commonAR compounds in cereal grains. The source of
whole-grains in food products can be distinguished by determina-
tion of the AR C17:0/C21:0 ratio, which is 1.0 inwhole grain rye, 0.1
in whole grain wheat and 0.01 in whole grain durum wheat [13].
Alkylresorcinol homologues are absorbed through the lym-
phatic system, distributed in association with lipoproteins in the
blood [14], present in adipose tissue [15] and metabolised in the
http://dx.doi.org/10.1016/j.jchromb.2015.07.009
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liver into two main metabolites, which are present in free or conju-
gated forms [16]. These metabolites are 3-(3, 5-dihydroxyphenyl)-
1-propanoic acid (DHPPA) and 3,5-dihydroxybenzoic acid (DHBA).
In a recent study, 5-(3,5-dihydroxyphenyl) pentatonic acid
(DHPPTA) and 2-(3,5-dihydroxybenzamido) acetic acid (DHBA-
glycine) were also described as urinary metabolites derived from
AR [17]. Moreover, 3,5-dihydroxycinnamic acid (DHCA) and 3,5-
dihydroxycinnamic acid amide (DHCA-amide) have recently been
identiﬁed in urine and suggested as AR metabolites [18].
To allow determination of AR in plasma, adipose tissues and
their metabolites in urine samples for epidemiological studies,
rapid and sensitive methods are needed. In this study, we sought
to develop optimized gas chromatography–mass spectrometry
(GC–MS) methods for rapid, sensitive and robust determination of
AR in plasma and small adipose tissue biopsies and for the ﬁrst
time for simultaneous determination of all currently reported AR
metabolites in urine (DHBA, DHPPA, DHPPTA, DHBA-glycine, DHCA
and DHCA-amide).
2. Materials and Methods
2.1. Chemicals and standards
All reagents used were of HPLC or gradient grade. Diethyl ether,
ethanol, ethyl acetate, formic acid, hexane and methanol were
purchased from Merck (Darmstadt, Germany). Alkylresorcinol ref-
erence compounds (C17:0, C19:0, C21:0, C23:0 and C25:0) and
AR internal standards (C20:0, C22:0, C24:0 and C26:0) were of
>95% purity and were purchased from ReseaChem Life Sciences
(Burgdorf, Switzerland). An AR internal standard (IS) mixture was
prepared by mixing AR C20:0, C22:0, C24:0 and C26:0 in methanol
(300g L−1 for each homologue). The AR metabolites (DHBA,
DHPPA, DHPAA, DHPPTA and DHBA-glycine) were of >95% purity
and were purchased from ReseaChem (Burgdorf, Switzerland),
while DHCA (98% purity) and DHCA-amide (78% DHCA-amide,
17% DHCA and 5% other unidentiﬁed compounds) were synthe-
sized at Vontor (Ing. T. Vontor, Pardubicka 628, Hradec Kralove
IV, Czech Republic) as described by Wierzbicka et al. [18]. Impu-
rities of DHCA-amide were corrected for in all analyses. Syringic
acid, used as an internal standard for the determination of AR
metabolites in urine samples (297g mL−1), and Type H-1 -
glucuronidase/sulphatase from Helix pomatia, used for hydrolysis
of AR metabolites in urine, were purchased from Sigma Chemi-
cals (St. Louis, MO, USA). Oasis® Max 60mg solid phase extraction
(SPE) cartridges were obtained from Waters (Milford, MA, USA)
and N, O bis (trimethylsilyl) triﬂuoroacetamide (BSTFA) with 1%
trimethylchlorosilane (TMCS) was purchased from Thermo Scien-
tiﬁc (Rockford, IL, USA). Stainless steel beads (diameter 2.8mm)
were purchased from VMR, Sweden. Triﬂuoroacetic anhydride
(TFAA) (99%, ReagentPlus®) and undecane (99%) were purchased
from Sigma–Aldrich, Sweden.
2.2. Sample analysis
2.2.1. Determination of AR in plasma samples
Plasma sample extraction and cleanup was conducted as
described previously [19], but a new method for derivatisation
and quantiﬁcation using gas chromatography–mass spectrometry
(GC–MS) was developed in order to obtain more stable samples,
improve method precision and shorten GC–MS run time. In brief,
plasma (200L) was pipetted into a disposable test tube and 15L
of AR internal standard mixture were added. The sample was vor-
texed for 1min, followed by extraction with diethyl ether (3mL)
for 2min on a multi-sample vortexer. The water phase was frozen
in an ethanol-dry ice bath, while the organic phase was poured off
into a new tube. The liquid–liquid extraction was repeated in total
three times and organic extracts were combined and evaporated to
dryness at 35 ◦C under a gentle streamof nitrogen.Methanol (1mL)
was added, and the test tube was vortexed before sample cleanup
with SPE. Sample extracts from all matrices reported in this paper
were puriﬁed on an SPE-robot as follows: Cartridges were condi-
tioned with 1mL 0.1M NaOH in MeOH (3:7, v/v) at a ﬂow rate
of 1mL min−1, sample extract was applied (1mL min−1), neutral
lipophilic compounds were washed away with 3mL MeOH (1mL
min−1) andARwereelutedwith2% formicacid inMeOH(2mL). Elu-
ates were evaporated to complete dryness under a nitrogen stream
at 60 ◦C.
Evaporated plasma extracts were derivatised with TFAA
(200L) for 30min in sealed test tubes. Following derivatisation,
the solution in the test tubewas transferred to a GC-vial with insert
and TFAA was removed to avoid column damage by evaporation
at 60 ◦C until dryness (usually around 10mins). The sample was
reconstituted in 20L undecane and sealed with a cap.
Derivatised samples and AR reference compounds were
analysed on GC–MS (Finnigan TM Trace GC Ultra Gas chro-
matograph coupled to a Finnigan Trace DSQ II mass detector,
Thermo Fisher Scientiﬁc, Waltham, MA, USA). A ZB-5MS column
(15m×0.25mm×0.25m, Zebron) was used. Helium (1.0mL
min−1) was used as the carrier gas. The temperature of the transfer
line was 310 ◦C and that of the ion source 250 ◦C.
A 2L sample was injected into a programmed temperature
vaporizing (PTV) injector with a steel liner set at 320 ◦C. The oven
temperature program was as follows: 200 ◦C was maintained for
2min and then raised to 310 ◦C within 2.2min. The temperature
was kept at 310 ◦C for 5min.
Electron impact ionization (EI) and negative chemical ionisation
(NCI) with methane as reagent gas were tested. The EI at 70 eV was
chosen for the applications described in this work due to consider-
ably higher abundance and less frequent cleaning of the ion source
required to ensure high sensitivity. Derivatized AR reference com-
pounds were analyzed in scan-mode (m/z 50–660) to characterize
fragmentation pattern and select suitable ions for quantiﬁcation.
Samples and standards were analyzed in selected ion monitor-
ing (SIM) mode with 2–3 ions per acquisition window to ensure
highest sensitivity. In samples, AR homologues were identiﬁed by
their characteristic base ion at m/z 316, their molecular ions and
by comparing their retention times with those of a mixture of syn-
thetic AR standards (C17:0–C25:0). The base ion m/z 316, rather
than the molecular ions m/z 540 (C17:0), 568 (C19:0), 596 (C21:0),
624 (C23:0) and 652 (C25:0), was used for quantiﬁcation of AR due
to higher selectivity and sensitivity for that ion compared with the
molecular ions. Peak width was recorded and dwell time was care-
fully evaluated to ensure adequate sensitivity and to ensure that
more than 10 data points were collected for each peak. The dwell
time of molecular ions and base ion was set to 10ms and 100ms,
respectively. A multipoint standard curve (5–500pg L−1, n=9,
corresponding to sample concentration range 1–300nmol L−1 for
each AR homologue) was used for quantiﬁcation of AR homologues
C17:0-C25:0 in each sample batch. Known AR concentrations were
linearly regressed against the ratio of AR/internal standard, C20:0
was used as internal standard for all homologues in plasma sam-
ples.
2.2.2. Determination of AR in adipose tissue samples
A pig adipose tissue sample (about 50g) was homogenized
by Lourdes Multi-mix homogenizer and used for method evalua-
tion. Different amounts of homogenized pig adipose tissue (10.2,
16.9, 26.4, 30.6, 35.0 and 54.0mg) were transferred to six dis-
posable plastic vials (screw-top micro-tube, 2mL, PP, Sarstedt AG,
Nürnbrecht, Germany) randomly loaded with different numbers of
2.8mm diameter stainless steel beads (1–6 per vial), in order to
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evaluate the effect of sample amount and number of beads needed
for quantitative extraction of AR. The AR internal standard mix-
ture (15L) and diethyl ether (1mL) were added and the vials
were sealed and extracted three times in a FastPrep®-24 Instru-
ment (MP Biomedicals, Solon, OH, USA) at a speed of 4.5 for 20 s
with 1min rest interval between runs. The samples were trans-
ferred to Eppendorf tubes and centrifuged for 10mins at 1792× g
in an Eppendorf 5417C centrifuge (Hamburg, Germany) to sepa-
rate connective tissue and organic solvent. The supernatants were
transferred to new test tubes and evaporated to dryness at 35 ◦C
under a gentle stream of nitrogen. Methanol (1mL) was added
and the test tubes were vortexed for 30 s and stored at 4 ◦C for
30min to crystallise fat. Sample extracts were ﬁltered through a
0.45msyringeﬁlter (GHPAcrodisc® PallGelmanLaboratory,USA)
to remove fat crystals and other solid particles, followed by sam-
ple cleanup with SPE as described for plasma samples (see Section
2.2.1). The evaporated adipose tissue sample extracts eluted from
SPEwerederivatisedwithTFAA(300L) for1hat40 ◦C in test tubes
sealed with caps. After derivatisation, the solutions were trans-
ferred to GC vials with inserts and TFAA was removed to avoid
column damage by evaporation at 60 ◦C until dryness (∼15min).
Samples were then reconstituted in 30L undecane and sealed
with a cap. GC–MS analysis of AR in adipose tissue samples was
conductedasdescribedabove forplasmasampleswitha fewexcep-
tions: 2L was injected into a split–splitless injector with a glass
liner (unpacked, straight design) set at 300 ◦C. The oven tempera-
ture program was as follows: 170 ◦C was maintained for 2min, and
then raised to 310 ◦C within 2.8min. This temperature was held for
5min. Individual AR internal standards were used for quantiﬁca-
tion of C17:0 (C20:0), C19:0 (C20:0), C21:0 (C22:0), C23:0 (C24:0)
and C25:0 (C24:0) in adipose tissue samples. Human subcutaneous
adipose tissue biopsy samples (10–50mg)were extracted similarly
as for pig adipose tissue, with six steel beads per sample. After sus-
pension in undecane, the sealed GC vials were heated for 10min
at 60 ◦C and vortexed for 20 s to ensure that derivatised AR were
recovered in the undecane.
2.2.3. Determination of AR metabolites in urine samples
Three different urine samples from a previous study [20]
were processed in quadruplicate using a modiﬁcation of a pre-
viously reported method for determination of DHBA and DHPPA
[21]. The procedure comprises enzymatic hydrolysis of conjugated
AR metabolites, extraction of the deconjugated compounds by
liquid–liquid extraction, puriﬁcation on SPE columns and deriva-
tization of AR metabolites before quantiﬁcation by GC–MS.
To evaluate the most suitable hydrolysis procedure for all
reported AR metabolites, different enzyme concentrations (12.2,
25, 40, 50 and 70mU) were used. In the ﬁnal protocol, urine sam-
ples (50L) were incubated overnight at 37 ◦C with hydrolysis
buffer (740L 0.1M sodium acetate buffer pH 5, containing 25
mU -glucuronidase/sulphatase from H. pomatia) and IS (10L).
Hydrolysis was stopped and pH adjusted by adding concentrated
HCl (15L). Samples were extracted with ethyl acetate (3mL) by
vortexing for 2min followed by centrifugation at 700–1000× g for
3min. Phases were then separated by freezing the water phase
using adry ice-ethanol bath. Theorganic phase containingdeconju-
gatedmetaboliteswaspouredoff intoanewtubeand theextraction
procedure was repeated once again. The pooled organic extracts
were evaporated to dryness under a nitrogen stream at 60 ◦C and
dissolved in MeOH (1mL). Urine samples were puriﬁed by SPE as
described forplasmaandadipose tissueandpuriﬁedextracts eluted
from SPE were evaporated to dryness under a nitrogen stream at
60 ◦C.
To determine a suitable derivatisation procedure, a standard
sample (100L) was mixed with four different ratios of BSTFA
and TMCS (70:30; 80:20; 90:10; 99:1) and incubated for 60min,
90min and 120min. The experiment was conducted in dupli-
cate. In the ﬁnal protocol, derivatisation was performed by adding
BSTFA+TMCS (99:1, v/v, 100L) and incubating for 70min at 60 ◦C.
The entire volume was transferred to GC vials for analysis.
Human urine samples were analyzed by GC–MS as described
for plasma samples with a few modiﬁcations: The sample vol-
ume injected was 1.5L and the injector temperature was 250 ◦C.
The oven temperature programme was as follows: 100 ◦C was
maintained for 2min and increased to 300 ◦C within 5min. This
temperature was held for 5min. Samples were quantiﬁed in EI-SIM
mode using molecular ions and at least one conﬁrmatory ion.
2.3. Evaluation of methods
2.3.1. Determination of AR in plasma
Speciﬁcity was evaluated as non-interference at the retention
times of the respective analyte from endogenous matrix compo-
nents and internal standardusing theproposed sample preparation
procedure and GC–MS conditions. The linearity was evaluated
using calibration standards (5–500pg L−1 for each AR homo-
logue, n=9, corresponding to plasma AR concentration in the range
3–300nmol L−1 for each AR homologue). The theoretical limits
of detection (LOD) and quantiﬁcation (LOQ) were determined as
the concentration where signal to noise ratio (S/N) was 3 and
10, respectively, based on determined S/N of AR homologues in a
plasma sample with low endogenous analyte concentration (total
AR concentration was 35nmol L−1).
The recovery was assessed by spiking a plasma quality control
sample with three different amounts of AR homologues at ﬁnal
concentrations corresponding to expected low, medium and high
analyte concentrations, corresponding to 150, 300 and 450nmol
L−1, respectively, of total AR in authentic samples. Four replicate
samples were prepared at each spiking level.
Recovery was calculated according to equation:
%Recovery=
[
(Analysed content − Endogenous content)
Spiked content
]
× 100
Precision was estimated by replicate determinations (n=4) of
AR homologues and their sum in a plasma quality control sample
performed over a one-week period. Intra- and inter-batch coef-
ﬁcients of variation (CVs) were calculated. The stability of TFAA
derivatives of AR in undecane was tested by re-injecting a batch
of samples (n=200) after storage for two weeks at room temper-
ature. The new modiﬁed method presented here was compared
with a previous method used in our laboratory [19] by analyzing
76 plasma samples with both methods. Method agreement for AR
homologues was evaluated by Bland–Altman plots.
2.3.2. Determination of AR in adipose tissue samples
Speciﬁcity, the theoretical limits of detection (LOD) and quan-
tiﬁcation (LOQ) and precision were evaluated as for plasma
samples. The recovery was assessed by spiking a human adipose
tissue sample with three different amounts of AR homologues at
ﬁnal concentrations corresponding to expected low, medium and
high authentic samples analyte concentrations (8–600ng g−1 for
eachARhomologue in samplemass range10–50mg). Four replicate
samples were prepared for each spiking level.
2.3.3. Determination of AR metabolites in urine
The linearity, theoretical limit of detection (LOD), limit of quan-
tiﬁcation (LOQ), recovery, and precisionwere assessed as described
above for plasma and adipose tissue samples. An eight-point stan-
dard calibration curve (0.8–103, 0.7–88, 0.6–76, 0.7–89, 0.7–89 and
0.6–76mol L−1 for DHBA, DHPPA, DHPPTA, DHCA, DHCA-amide
and DHBA-glycine) was used to evaluate linearity. Stability of the
metabolites inhumanurine sampleswasassessedbyanalyzing four
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Fig. 1. Formation of triﬂuoroacetic anhydride (TFAA) derivatised 5-n-alkylresorcinols and their detected fragments in electron impact ionisation (EI). R=C16H33–C24H49.
different standard samples corresponding to low,mediumandhigh
concentrations at four different occasions during one week.
2.4. Statistical analysis
General linearmodel (GLM)wasused to evaluate silylation yield
betweendifferent BSTFA/TMCS ratios and incubation times entered
as ﬁxed factors. Linear regression was applied to examine the sta-
bility of the AR metabolites by entering time (days) as a continuous
variable and sample concentration (n=4 levels) as a ﬁxed factor.
Minitab 16 (State College, PA, USA) was used for statistical analysis
and P<0.05 was considered statistically signiﬁcant.
3. Results and discussion
Slightly different GC–MS methods were developed or modi-
ﬁed to allow rapid and repeatable quantiﬁcation of the ﬁve most
common AR homologues in plasma and adipose tissue and six AR
metabolites in human urine samples. Themethods developedwere
evaluated according to the European Union decision 2002/657/EC
[22]. To our knowledge, this is the ﬁrst published report of an eval-
uated GC–MS method for determination of AR in small sample
adipose tissue biopsies and for simultaneous determination of all
currently reported AR metabolites in human urine.
3.1. Determination of AR in plasma
The extraction and clean-up of AR in plasma samples has been
thoroughly evaluated before [19], thus these steps were applied
without any changes in the current procedure. However, a new
derivatization technique using TFAA was evaluated in the current
method to increase sample stability, yield and thereby increase
overall precision and sensitivity. A fasterGC-programwas alsoused
(10min instead 30min). The molecular ions m/z 540 (C17:0), 568
(C19:0), 596 (C21:0), 624 (C23:0) and 652 (C25:0) and a common
base ion at m/z 316 were found on analyzing TFAA-AR derivatives
in AR reference compounds. The masses of molecular ions showed
that both phenolic groups of the AR homologues were derivatized
by TFAA under the conditions used. The mass difference between
molecular ions and the common base ion showed that AR deriva-
tized with TFAA share the same fragmentation pattern (Fig. 1)
as silylated AR [16]. A typical GC–MS (EI-SIM) chromatogram of
the base ion and the molecular ions of TFAA-AR derivatives in a
blank and in a plasma sample after whole grain wheat and rye
consumption are shown in Fig. 2a and b. The molecular ions m/z
540 (C17:0), 568 (C19:0), 596 (C21:0), 624 (C23:0) and 652 (C25:0)
and a common base ion at m/z 316 were selected for identiﬁcation
and quantiﬁcation of AR in plasma based on their abundance in
the reference standard mixture (Fig. 2). The AR homologues eluted
within 10min and were well separated, with no obvious interfer-
ences for either base ion or molecular ions (Figs. 1 and 2a and b).
The abundance of molecular ions ranged from 1.6 to 8.3% of base
ion for the different AR homologues under EI conditions (data not
shown).
The method developed showed good linearity (r2 >0.99) for all
AR homologues in the concentration range tested (5–500pg L−1
for each AR homologue, corresponding plasma total AR concen-
trations in the range 15–1500nmol L−1). This covers most real
sample conditions (geometric mean total AR is 35–41nmol L−1
in the Central European and Scandinavian countries and <23nmol
L−1 in the Mediterranean countries [23]). The LOD for AR homo-
logues was 0.04 (C17:0), 0.05 (C19:0), 0.02 (C21:0), 0.02 (C23:0)
and 0.09 (C25:0) nmol L−1 and LOQ was 0.13 (C17:0), 0.17 (C19:0),
0.06 (C21:0), 0.06 (C23:0) and 0.30 (C25:0) nmol L−1. The intra-
and inter-batch CV for determination of AR homologues in a
plasma quality control sample was <10% and <15%, respectively
(Table 1). Recovery was between 76 and 118% for all homologues
(Table 1). Maintenance of the GC system, including cutting the col-
umn 30–40 cm at the inlet side, changing liner and septum and
cleaning the ion source, was typically conducted after injection of
about 200 samples, in order to ensure adequate LOD and LOQ.
Results forAR concentrations in200 samplesdetermined imme-
diately and after 2 weeks at room temperature showed excellent
agreement (r>0.996, P<0.001 for C17:0–C25:0, data not shown).
This shows that TFAA-derivatised AR homologues are stable in
undecane for at least two weeks. The average difference and lim-
its of agreement (bias±1.96× SD) between the previous method
for determination of AR in plasma [19] and the slightly modi-
ﬁed method presented here was 1.6±4.4, −3.2±9.1, 1.1±14.5,
−0.5±6.2 and −2.2±10.5nmol L−1 for C17:0, C19:0, C21:0, C23:0
and C25:0, respectively (Fig. 3). There was no signiﬁcant propor-
tional error (P>0.05 for slope in the Bland–Altman plot). The small
bias and absence of proportional error show that the two methods
can be used interchangeably.
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Fig. 2. Electron impact-selected ion monitoring (EI-SIM) of the base ion (m/z 316 for C17:0, C19:0, C20:0 (internal standard), C21:0, C22:0 (internal standard), C23:0, C24:0
(internal standard), C25:0 and C26:0 (internal standard)), and the molecular ions of AR homologues (m/z 540, 568, 582, 596, 624 and 652 for C17:0, C19:0, C20:0 (internal
standard), C21:0, C23:0, C25:0, respectively). (a) blank, (b) human plasma sample with total AR concentration 134.8nmol L−1 and (c) human adipose tissue with total AR
concentration 0.840nmol g−1.
Table 1
Within- and between-batch precision for determination of alkylresorcinols (AR) in a plasma sample used as an in-house quality control sample (n=4 per batch, 3 batches in
total) and recovery (n=4 for each spiking level) after spiking with 10, 20 and 30ng of total AR as the sum of equal amounts of spiked C17:0, C19:0, C21:0, C23:0 and C25:0.
AR Average concentration(nmol L−1) Within-batch CV (%) Between-batch CV (%) Recovery after spiking (%)
10nga 20ngb 30ngc
C17:0 5.7 3.3 5.9 110 109 110
C19:0 17.2 1.8 8.5 97 91 118
C21:0 18.8 2.6 12.4 90 94 110
C23:0 6.6 3.2 2.6 83 76 98
C25:0 7 7.5 8.8 99 106 101
a Sum of spiked amount of AR C17:0–C25:0 (2ng per homologue), corresponding to plasma total AR concentration 150nmol L−1.
b Sum of spiked amount of AR C17:0–C25:0 (4ng per homologue), corresponding to plasma total AR concentration 300nmol L−1.
c Sum of spiked amount of AR C17:0–C25:0 (6ng per homologue), corresponding to plasma total AR concentration 450nmol L−1.
3.2. Determination of AR in adipose tissue biopsies
A typical GC–MS (EI-SIM) chromatogram of the base ion and the
molecular ions of TFAA-AR derivatives in an adipose tissue sample
after whole grain wheat and rye consumption is shown in Fig. 2c.
Adipose tissue needle aspiration biopsy samples are typically in
the range 10–50mg and the sample amount varies between collec-
tions. Different amounts of adipose tissue sample in combination
with different numbers of steel beads were therefore evaluated in
order to ensure quantitative extraction, irrespective of variations in
sample amount used. Different organic solvents and their mixture
were previously evaluated for extraction of AR and pure diethyl
ether showed the best results [19]. Determined AR content in pig
adipose tissue samples (n=6, 10.2–54.0mg) homogenized with a
random number of stainless beads (n=1–6) in pure diethyl ether
(1mL) was excellently correlated with the corresponding sample
mass (Fig. 4), suggesting that any combination of sample amount
and number of beads in the tested range could be used. In the ﬁnal
protocol for human adipose tissue, six steel beads were used to
ensure disintegration of connective tissue, which can be abundant
in some needle aspiration biopsy samples. In comparison with a
previous method where a Heidolph Diax 600 homogeniser (Hei-
dolph, Kelheim, Germany) [15] was used for extraction of each
sample, the current steel bead extraction method allowed simul-
taneous analysis of 30 samples. This makes the current method
considerably faster and less prone to contamination errors. Heat-
ing derivatised AR in undecane resulted in improved precision for
determination of all homologues (Table 2). The heating probably
improved the solubility of derivatised AR homologues in undecane
and this step was incorporated in the ﬁnal protocol.
Internal standards with different chain lengths (C20:0, C22:0,
C24:0, C26:0) were evaluated to provide a method with high preci-
sion, since the losses of AR homologues during sample preparation
differed due to their diverse lipophilicity and/or polarity. The AR
homologues C22:0, C24:0 and C26:0 were evaluated as internal
standards. C22:0workedwell for C21:0 andC23:0;while C24:0 and
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Table 2
Alkylresorcinols (AR) determined in a human adipose tissue sample without and with heat treatment after derivatisation.
AR Without heating (n=4) With heating (n=4)
Mean (nmol g−1) SD CV, (%) Mean (nmol g−1) SD CV, (%)
C17:0 0.04 0.009 21.2 0.04 0.003 9.7
C19:0 0.58 0.075 12.8 0.66 0.009 1.3
C21:0 1.2 0.103 8.5 1.24 0.047 3.8
C23:0 0.12 0.025 20.3 0.15 0.005 3.2
C25:0 0.08 0.022 28.9 0.09 0.003 3.2
Total 2.03 0.205 10.1 2.18 0.045 2.1
AR, alkylresorcinol; CV, coefﬁcient of variation; SD, standard deviation.
Table 3
Within- and between-batch precision for determination of alkylresorcinols (AR) in a adipose tissue sample used as an in-house quality control sample (n=4 per batch, 3
batches in total) and recovery (n=4 for each spiking level) after spiking with 2, 10 and 30ng of total AR as the sum of equal amounts of C17:0, C19:0, C21:0, C23:0 and C25:0.
AR Average Concentration (pmol g−1) Within-batch CV (%) Between-batch CV (%) Recovery, (%)
2 nga 10 ngb 30 ngc
C17:0 4.7 13.7 16.4 109 95 102
C19:0 30.7 4.4 8.3 88 89 90
C21:0 86.8 3.5 11.3 61 81 92
C23:0 53.2 4.4 14.2 81 82 88
C25:0 88.8 4.1 12.0 105 109 95
a Sum of spiked amount of AR C17:0–C25:0 (0.4ng per homologue), corresponding to adipose tissue total AR concentration 40ng g−1 in 10mg of adipose tissue or 8ng g−1
in 50mg of adipose tissue.
b Sum of spiked amount of AR C17:0–C25:0 (2ng per homologue), corresponding to adipose tissue total AR concentration of 200ng g−1 in 10mg of adipose tissue or 40ng
g−1 in 50mg of adipose tissue.
c Sum of spiked amount of AR C17:0–C25:0 (6ng per homologue), corresponding to adipose tissue total AR concentration of 600ng g−1 in 10mg of adipose tissue or 120ng
g−1 in 50mg of adipose tissue.
Fig. 3. Bland–Altman plot of the difference between plasma total AR concentra-
tions determined by the present method minus results determined with a previous
method ([19] on the Y-axis and the average of the two methods on the X-axis. The
dotted lines show the limits of agreement (3.2±30.6nmol L−1) within which 95%
of the observations are found.
C26:0 worked well for C25:0. However, C24:0 was chosen, since it
showed higher S/N ratio than C26:0.
The LOD for AR homologues in adipose tissue was 0.04 (C17:0),
0.05 (C19:0), 0.02 (C21:0), 0.02 (C23:0) and 0.09 (C25:0) fmol
injection−1 and LOQ was 0.12 (C17:0), 0.16 (C19:0), 0.08 (C21:0),
0.07 (C23:0) and 0.31 (C25:0) fmol injection−1. Recovery was
between 81 and 109% for all homologues, except for C21:0 at low
spiking concentration (Table 3). Intra- and inter-day ARhomologue
CV was below 5% and 15%, respectively, except for homologue
C17:0, where the corresponding CV was 13.7 and 16.4%, respec-
tively (Table 3). The high inter-batch CV for C17:0 is probably due
to the low concentration of C17:0 in the human tissue sample used
for method evaluation.
Fig. 4. Linearity of determined total AR (C17:0–C25:0) content in pig adipose tissue
samples in response to different amount of pig adipose tissue (10–50mg) and the
number of stainless beads (n=1–6).
3.3. Determination of AR metabolites in urine
A slightly modiﬁed protocol based on a previous method [21]
was developed to allow accurate quantiﬁcation of four novel AR
metabolites recently identiﬁed (DHPPTA, DHBA-glycine, DHCA and
DHCA-amide) along with DHBA and DHPPA in urine samples
[17,18]. Enzymatic hydrolysis, extraction and SPE of DHBA and
DHPPA have been optimized previously [21], and similar condi-
tions were applied in the present method. However to evaluate the
most suitable hydrolysis procedure in order to ensure complete
hydrolysis for the newly identiﬁed AR metabolites, ﬁve levels of
enzymes were tested. The importance of the de-conjugation step
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Table 4
Concentrations of AR metabolites (mol L−1) in a urine sample (n=3), without and
with deconjugation. CV represents the within-batch coefﬁcient of variation (n=3).
Metabolite Concentration after
deconjugation,
mol L−1 (CV, %)
Concentration
without
deconjugation,
mol L−1 (CV, %)
DHBA 80.8 (8.0) 44.3 (8.2)
DHPPA 220.8 (8.7) 68.4 (7.2)
DHPPTA 17.8 (12.2) 2.2 (13.4)
DHCA 95.6 (7.2) 43.8 (8.3)
DHCA-amide 254. 0(14.3) 22.8 (12.5)
DHBA-glycine 271.0 (13.3) 300.1 (14.2)
was conﬁrmed for DHPPTA, DHCA and DHCA-amide by compar-
ing urine concentrations before and after deconjugation (Table 4).
The amount of enzyme optimized for deconjugation of DHBA and
DHPPA [21] was also found to be suitable for the new metabolites
by testing four different levels (data not shown). Deconjugation
did not affect DHBA-glycine concentration, which shows that this
molecule is not sulphated or glucuronidated. The obtained results
demonstrated thatDHPPTA,DHCAandDHCA-amideareexcreted in
urine in free form and as conjugates, as shown previously for DHBA
and DHPPA [21,24,25]. Similar extraction and SPE conditions as for
the previous method [21] were used.
The efﬁciency of derivatisation of OH- groups and the COOH-
group of AR metabolites may differ between metabolites [26].
Therefore we optimized the derivatisation procedure to ensure
appropriate derivatization of the novel AR metabolites. The results
showed, that when comparing derivatization conditions, i.e. the
proportion of BSTFA/TMCS in the silylation mixture and the dura-
tion of the reaction, signiﬁcantly larger peak areas were obtained
for DHCA (P<0.009) and DHPPTA (P<0.01) when using 70:30
Table 5
Recovery of alkylresorcinol (AR) metabolites in a human urine sample spiked with
AR metabolites corresponding to low, medium and high total urinary AR metabolite
concentrations.
AR metabolite Recovery, (%)
Lowa Mediumb Highc
DHBA 111 106 108
DHPPA 84 95 92
DHCA 98 99 94
DHPPTA 72 85 80
DHCA-amide 51 88 88
DHBA-glycine 70 97 95
a 30L of standard mix (2g/mL). The added amounts corresponded to 6.9, 5.9,
4.2, 5.1, 3.7 and 10.5mol/L urine for DHBA, DHPPA, DHPPTA DHCA, DHCA-amide
and DHBA-glycine, respectively.
b 150L of standard mix (2g/mL). The added amounts corresponded to 48.1,
43.3, 33.5, 45.3. 25.4 and27.5mol/L urine forDHBA,DHPPA,DHPPTADHCA,DHCA-
amide and DHBA-glycine, respectively.
c 300L of standard mix (2g/mL). The added amounts corresponded to 78.1,
69.1, 59.7, 78.3, 63.8 and58.5mol/L urine forDHBA,DHPPA,DHPPTADHCA,DHCA-
amide and DHBA-glycine, respectively.
BSTFA/TMCS, whereas no signiﬁcant difference was found for
DHCA-amide (P<0.383) and DHBA-glycine (P<0.347). However,
the differences were ≤20% and since a BSTFA/TMCS ratio of 70:30
would cause more extensive contamination of the GC–MS instru-
ment and cause problems with the injection syringe, the ratio 99:1
was used as before for DHBA and DHPPA [16,21]. Moreover, there
was no signiﬁcant effect of silylation time, suggesting that 70min,
which is 10min longer compare to previous method, was sufﬁcient
for complete silylation of all metabolites. When analysing several
batches, the derivatisation step should preferably be conducted for
all batches at the same time, in order to obtain satisfactory preci-
sion (Table 6) whereas silylation at different occasions give higher
CVs (data not shown).
Fig. 5. Total ion chromatogram (1) and selected ionmonitoring (SIM) chromatograms formolecular ions fromDHBA (2), SA (3), DHPPA (4), DHPPTA (5), DHCA (6), DHCA-amide
(7) and DHBA-glycine (8) in (A) standard solution and (B) a blank urine sample treated according to the experimental protocol.
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Fig. 6. Electron impact (EI) spectra for DHBA, DHPPA, DHCA, DHPPTA, DHCA- amide and DHBA-glycine in standard solution.
A GC–MS (EI-SIM) chromatogram of the proﬁle of AR metabo-
lites in a standard solution and in a typical urine sample after
whole grain wheat and rye intake is shown in Fig. 5. The current
method has been modiﬁed in order to obtain faster run times, good
separation and adequate precision for simultaneous quantiﬁcation
of already reported and novel AR metabolites. After optimiza-
tion of the temperature programme, all metabolites were well
separated within 7min. This is 9min faster than in the previ-
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Table 6
Within- and between batch precision for determination of AR metabolites in three different human urine samples (n=3).a
Metabolite Sample Batch 1 Batch 2 Batch 3
Mean CV
(%)
Mean CV (%) Mean CV (%) Meanb CVc (%)
(mol L−1) (mol L−1) (mol L−1) (mol L−1)
DHBA 1 35.5 6.1 42.3 6.6 54.3 3.7 44.1 20.0
2 7.9 7.8 10.1 2.6 7.5 18.5 8.5 16.2
3 30.1 12.7 28.3 26.8 29.8 25.7 29.4 3.2
DHPPA 1 76.1 2.7 74.1 3.18 77.4 5.3 75.8 2.3
2 21.3 2.5 22.7 2.6 14.3 21.2 19.5 23.1
3 112.2 3.5 117.9 4.9 116.6 3.4 115.5 2.6
DHCA 1 20.5 5.1 19.2 2.7 21.5 8.3 20.4 5.6
2 5.1 6.7 5.2 1.4 3.7 8.8 17.9 17.9
3 19.9 2.7 23.6 9.2 23.1 7.1 22.3 8.9
DHPPTA 1 4.3 6.1 3.9 4.26 4.3 7.0 4.2 5.0
2 0.6 14.4 0.6 18.6 0.2* 4.5 0.6 4.5
3 7.2 5.8 7.6 6.9 7.1 3.5 7.3 3.3
DHCA-
amide
1 41.8 7.2 44.3 3.1 44.4 8.1 43.5 3.4
2 54.5 12.7 55.5 13.9 45.7 5.4 51.8 10.4
3 57. 7.1 64.7 3.4 63.8 13.8 61.9 6.5
DHBA-
glycine
1 33.9 8.7 37.7 3.2 33.6 12.3 35.1 6.5
2 7.1 9.4 7.3 6.6 4.4 22.9 6.2 25.1
3 25.3 4.1 26.6 16.9 25.8 16.4 25.9 2.5
*Error during the sample preparation, value not included in estimation of inter-batch CV.
a All batches were derivatized at the same day.
b Mean concentration (mol L−1) between days
c CV, coefﬁcient of variation between days.
ous method for determination of DHBA and DHPPA [21]. Silylated
derivatives of DHBA, DHPPA, DHPPTA, DHCA, DHCA-amide and
DHBA-glycine in human urine samples were identiﬁed by com-
paring their retention times and EI spectra with those of standard
compound (Figs. 5 and 6). These optimizedGC–MS conditionswere
applied to a large number of samples. Sensitivity of themethodwas
highly dependent on the instrument conditions and therefore ion
source cleaning was performed and 40–50 cm of column was cut
at the inlet side and the liner was change after 200 injections to
ensure high sensitivity.
The theoretical LOD was estimated using a urine sample with
low AR metabolite concentration to be 0.31 (DHBA), 1.5 (DHPPA),
0.1 (DHCA), 0.1 (DHPPTA), 0.4 (DHCA-amide) and 0.1 (DHBA-
glycine) mol L−1. The LOQ was 1.0 (DHBA), 5.0 (DHPPA), 0.3
(DHCA), 0.5 (DHPPTA), 1.2 (DHCA-amide) and 0.4 (DHBA-glycine)
mol L−1. The regression analysis showed no deviation from lin-
earity in the sample concentration range 2.2–77.9mol L−1. The
correlation of coefﬁcient (R2) was 0.990, 0.993, 0.991, 0.995, 0.983
and 0.989 for DHBA, DHPPA, DHCA, DHPPTA, DHCA-amide and
DHBA-glycine, respectively.
The mean recovery of all spiking levels tested was 108%,
90%, 97%, 80%, 75% and 88% for DHBA, DHPPA, DHCA, DHPPTA,
DHCA-amide and DHBA-glycine, respectively (Table 5). Intra-batch
coefﬁcient of variation (CV) assessed on triplicate samples at
three different concentration levels was on average ≤8.7%. The
inter-batch CV was on average ≤9.7%, showing adequate method
reliability (Table 6). No signiﬁcant trend in AR metabolite concen-
tration was found by delayed sample analysis over a period of 4
days, showing that silylated samples can be stored for at least 4
days at room temperature before analysis.
4. Conclusions
High-throughput GC–MS methods for quantiﬁcation of AR
homologues C17:0-C25:0 in human plasma and adipose tissue and
all currently reported AR metabolites (DHBA, DHPPA, DHPPTA,
DHBA-glycine, DHCA and DHCA-amide) in human urine were
developed and evaluated. All methods showed good sensitivity,
accuracy and precision. Methods for determination of AR in plasma
and adipose tissue samples also had considerably shorter GC–MS
run-time, considerably higher sample extraction through put (adi-
pose tissue), improved precision and lower LOD/LOQ than previous
methods. In summary, these methods could be used for assess-
ment ofwhole grainwheat and rye intake biomarkers in large-scale
epidemiological studies.
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